baclofen has been researched along with acamprosate in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 6 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Egli, M; Heilig, M | 1 |
| Johnson, BA | 1 |
| Garbutt, JC | 1 |
| Heinz, A; Müller, CA | 1 |
| Bertrand, V; Boucard, A; Callizot, N; Cholet, N; Chumakov, I; Cohen, D; Foucquier, J; Graudens, E; Guedj, M; Hajj, R; Maurice, T; Milet, A; Nabirotchkin, S; Pereira, Y; Scart-Grès, C; Steinschneider, R; Toulorge, D; Traoré, S; Vial, E | 1 |
| Lieb, M; Soyka, M | 1 |
| Borro, P; Leone, S; Testino, G | 1 |
| Cholet, N; Chumakov, I; Cohen, D; Foucquier, J; Guedj, M; Hajj, R; Laffaire, J; Milet, A; Mitry, R; Nabirotchkin, S; Robelet, S; Toulorge, D | 1 |
| Goh, ET; Morgan, MY | 1 |
| Lyon, J | 1 |
| Barkley-Levenson, A; Crabbe, JC; Hack, WR; Huang, LC; Metten, P; Ozburn, AR; Schlumbohm, JP; Spence, SE | 1 |
| Boussageon, R; Duprez, R; Huneau, A; Laviolle, B; Locher, C; Naudet, F; Palpacuer, C | 1 |
| Donoghue, K | 1 |
| Diouf, M; González-Marín, MC; Jeanblanc, J; Lebourgeois, S; Naassila, M | 1 |
| Chaignot, C; Coste, J; Dray-Spira, R; Rey, G; Weill, A; Zureik, M | 1 |
| Minozzi, S; Rösner, S; Saulle, R | 1 |
| Alho, H; Castrén, S; Mäkelä, N | 1 |
| Paille, F | 1 |
| Boussicault, L; Callizot, N; Cohen, D; Hajj, R; Laffaire, J; Nabirotchkin, S; Rinaudo, P; Schmitt, P | 1 |
| Burnette, EM; Gillis, AJ; Grodin, EN; Hurley, B; Meredith, LR; Miotto, K; Nieto, SJ; Ray, LA | 1 |
| Cheng, A; Habtemariam, Z; Kelleher, C; Lewis, H; Lovendoski, J; Strathie, K; Tyson, LD | 1 |
| Giri, S; Sundaram, S | 1 |
| Lewis, H; Tyson, LD | 1 |
| Agabio, R; Minozzi, S; Rösner, S; Saulle, R | 1 |
12 review(s) available for baclofen and acamprosate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate | 2006 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2008 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate | 2009 |
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate | 2013 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline | 2015 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome | 2017 |
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate; Treatment Outcome | 2018 |
Baclofen for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Craving; Depression; Female; GABA-B Receptor Agonists; Humans; Male; Middle Aged; Patient Dropouts; Randomized Controlled Trials as Topic; Recurrence | 2018 |
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapentin; Humans; Naltrexone; Ondansetron; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Humans; Naltrexone; Topiramate | 2022 |
Baclofen for alcohol use disorder.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; Middle Aged; Naltrexone | 2023 |
14 other study(ies) available for baclofen and acamprosate
| Article | Year |
|---|---|
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome | 2009 |
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.
Topics: Acamprosate; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apoptosis; Baclofen; Cells, Cultured; Disease Models, Animal; Drug Repositioning; Drug Synergism; Female; Humans; Male; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Wistar; Signal Transduction; Taurine | 2015 |
Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics; Alcoholism; Baclofen; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver Neoplasms; Pyridoxine; Pyrrolidonecarboxylic Acid; Risk Factors; Taurine | 2016 |
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.
Topics: Acamprosate; Animals; Baclofen; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drug Therapy, Combination; Female; Male; Nerve Degeneration; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Taurine | 2015 |
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.
Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Darkness; Disease Models, Animal; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Naltrexone; Taurine | 2017 |
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate | 2018 |
Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking.
Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Extinction, Psychological; Hydroxybutyrates; Male; Motivation; Naltrexone; Rats; Self Administration | 2018 |
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
Topics: Acamprosate; Administrative Claims, Healthcare; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Databases, Factual; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Off-Label Use; Risk Assessment; Socioeconomic Factors | 2018 |
[Medical management of alcohol use disorders].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Humans | 2019 |
Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis.
Topics: Acamprosate; Amyotrophic Lateral Sclerosis; Animals; Baclofen; Cell Survival; Cells, Cultured; Cerebral Cortex; Coculture Techniques; Drug Therapy, Combination; Female; GABA-B Receptor Agonists; Motor Neurons; Pregnancy; Rats; Rats, Transgenic; Rats, Wistar | 2020 |
Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Retrospective Studies | 2022 |
Acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis | 2022 |
Response to 'acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?'
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis | 2022 |